---
title: "12:43 ETOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289083566.md"
description: "The Schall Law Firm is investigating Oculis Holding AG (NASDAQ: OCS) for potential securities law violations. The inquiry focuses on whether the company issued misleading statements by claiming its Phase 3 DIAMOND trials were advancing as planned, only to announce their failure and halt FDA filing plans on May 29, 2026. Investors who suffered losses are encouraged to contact the firm to discuss their rights."
datetime: "2026-06-08T16:43:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289083566.md)
  - [en](https://longbridge.com/en/news/289083566.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289083566.md)
---

# 12:43 ETOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or "the Company") (NASDAQ: OCS) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Oculis claimed that its Phase 3 DIAMOND trials were "advancing as planned," but then announced on May 29, 2026, that both DIAMOND trials failed to meet their primary endpoints. The Company added that based on these results, it would not pursue an FDA filing for its drug candidate.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at \[email protected\].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

**CONTACT:**

The Schall Law Firm  
Brian Schall, Esq.  
310-301-3335  
\[email protected\]  
www.schallfirm.com

SOURCE The Schall Law Firm

### Related Stocks

- [OCS.US](https://longbridge.com/en/quote/OCS.US.md)
- [OCSAW.US](https://longbridge.com/en/quote/OCSAW.US.md)

## Related News & Research

- [OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm](https://longbridge.com/en/news/288771572.md)
- [Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles](https://longbridge.com/en/news/289047382.md)
- [Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference | OCS Stock News](https://longbridge.com/en/news/289092523.md)
- [12:04 ETENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm](https://longbridge.com/en/news/289080659.md)
- [12:09 ETXZO Investors Have Opportunity to Join Exzeo Group, Inc. Fraud Investigation with the Schall Law Firm](https://longbridge.com/en/news/289081170.md)